News
9d
Zacks.com on MSNAstraZeneca Boasts Strong Oncology Portfolio: Can It Sustain Growth?AstraZeneca AZN is one of the leading drugmakers in the oncology space. Oncology sales (comprising around 41% of AstraZeneca‘s total revenues) rose 13% in the first quarter of 2025, generating $5.6 ...
10d
Zacks.com on MSNSMMT Stock Gains on Rumored Licensing Talks With AstraZenecaSummit Therapeutics jumps 9% as AZN eyes a potential $15 billion licensing deal for its cancer drug, ivonescimab.
AstraZeneca has received another boost to its aspirations in oncology with the FDA approval of Calquence, a next generation treatment for mantle cell lymphoma (MCL). Calquence (acalabrutinib) is ...
Despite a Q1 revenue miss due to currency headwinds, core EPS beat expectations for AstraZeneca. Read why AZN stock is a Buy.
FDA approval of AstraZeneca’s Calquence in chronic lymphocytic leukaemia sets up showdown with AbbVie and J&J’s Imbruvica ...
16d
Zacks.com on MSNPfizer's Strong Late-Stage Pipeline Can Drive Long-Term GrowthPFE's robust late-stage pipeline, recent FDA wins and deep oncology bets position it for long-term growth through 2030.
AbbVie ABBV has built a substantial oncology franchise. Initially anchored by blood cancer drugs Imbruvica and Venclexta, the company has also been expanding its offerings into solid tumors. Its ...
During a live event, Andrew H. Lipsky, MD, and participants discussed balancing efficacy, safety, and patient preferences ...
AstraZeneca is in advanced talks with Summit Therapeutics over a potential $15 billion deal for the lung cancer drug ivonescimab.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results